Sentences with phrase «on ipilimumab»

This compared with 7.9 months and 5.6 months respectively for patients on nivolumab alone and 2.8 months and four months respectively for those on ipilimumab alone.

For those aged 75 and over (118 patients), the average progression - free survival time for those on the combination treatment could not be calculated as the patients» disease had not progressed yet; it was 5.3 months for those on nivolumab alone and four months for those on ipilimumab alone.

These adverse events resulted in 52 percent of patients on ipilimumab discontinuing treatment before its completion, including 39 percent of patients during the first four doses of ipilimumab.

Furthermore, 5 patients on ipilimumab died during treatment due to adverse events.

Out of a total of 945 patients in 20 different countries [3] who were randomised to receive the combination therapy or one of the drugs alone, those on the combination therapy survived for an average of 11.5 months without their disease progressing, compared, to 6.9 months for patients on nivolumab alone and 2.9 months for those on ipilimumab alone.

Not exact matches

The trial involved an experimental checkpoint inhibitor from Bristol - Myers Squibb called ipilimumab (now marketed as Yervoy)-- whose aim was to release the molecular brakes on her own army of T cells.

The drug's mechanism of action was entirely new: Instead of attacking cancer cells (like chemo), or indiscriminately revving up the immune system (like IL - 2), ipilimumab blocked a single receptor on one type of immune cell.

Ipilimumab works by releasing the brakes on T - cells so they can attack tumors.

Checkpoint inhibitors like ipilimumab — which has been on the market since 2011 — nivolumab, and pembrolizumab stop tumor cells from stimulating the receptors.

Ipilimumab targets the CTLA - 4 checkpoint on T cells and was the first immune checkpoint inhibitor.

Ipilimumab targets a protein called cytotoxic T lymphocytic antigen - 4 (CTLA - 4) that is found on a type of immune cell called a T cell.

Checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab have had a dramatic impact on treatment of several tumor types, including melanoma, lung cancer, head and neck cancers and others.

The drugs, ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), made by Bristol - Myers Squibb (BMS), are two immune checkpoint inhibitors that «release the brakes» on the immune system, allowing it to mount a stronger and more effective attack against cancer.

And again, that is an immunologic drug, and it was approved on the basis of prolonged relapse - free survival — that is, prolonged time to return of the tumor compared with ipilimumab, which as I mentioned was the standard since 2015.

The positive results from the two phase III studies of ipilimumab were made possible in part through the evolution of the clinical science, which is based on new models of academic - industry partnership to advance immunotherapy development.